Dimerix to continue supplying propagermanium to kidney disease patients
20 April, 2016The TGA's special access scheme has granted Dimerix the right to continue supplying propagermanium to participants in its DMX-200 clinical trial, upon clinician approval and participant agreement.
3D-printed sleep apnoea device cleared by FDA
08 April, 2016Oventus Medical has received clearance from the US FDA for the O2VENT device, an oral appliance intended to reduce or alleviate snoring and mild to moderate obstructive sleep apnoea.
Prolonged survival in graft-versus-host disease study
07 April, 2016Cynata Therapeutics has announced positive interim data from a proof-of-concept study of its lead Cymerus MSC product, CYP-001, with the product demonstrating prolonged patient survival.
Plans for Phase 3 smoking cessation trial underway
04 April, 2016Invion has met with the US FDA to discuss Phase 3 plans for development of oral INV102 (nadolol) as a treatment for patients with chronic obstructive pulmonary disease (COPD) who cannot quit cigarette smoking.
Repairing blood vessels to improve anticancer treatment
01 April, 2016A new drug could be used to repair the blood vessel defects that prevent current anticancer treatments from entering tumours.
IDT's new manufacturing partner
30 March, 2016WellSpring Pharma Services has agreed to manufacture two to three pharmaceutical products that require manufacturing processes or scale not currently available at IDT's Boronia facilities.
Wet AMD trial completes patient enrolment
30 March, 2016Opthea has completed patient enrolment in its ongoing phase 1 dose escalation clinical trial of OPT-302 as a novel therapy for wet age-related macular degeneration (wet AMD).
Accelerating anticancer drug discovery
29 March, 2016MecRx has secured a $4 million investment from the Medical Research Commercialisation Fund to advance its breakthrough technology for accelerating drug discovery.
$1 million for radiopharma company
21 March, 2016Clarity Pharmaceuticals is one of 15 lucky companies that this month received grant funding through Accelerating Commercialisation.
Hydrogel to enable tumour-targeting cancer treatment
21 March, 2016Researchers have developed a 3D-printable material that opens the way to personalised cancer treatment by enabling multiple, simultaneous tests to find the correct therapy to target a particular tumour.
Medical cannabis company AusCann to be bought by TWH
18 March, 2016TW Holdings has announced its intention to purchase medical cannabis company AusCann.
Dendrimer technology licensed for herbicide
18 March, 2016Starpharma's Priostar dendrimer technology has been licensed for the development of an enhanced 2,4-D herbicide for the US market.
Hep C drug trial deemed a success
17 March, 2016Shares in Biotron rose almost 60% as the company confirmed positive outcomes from its Phase 2 study of antiviral drug BIT225 in Hepatitis C patients.
POC diagnostics market to reach almost $3 billion by 2021
14 March, 2016GlobalData has projected that the point-of-care (POC) diagnostics market will experience solid growth from $2.13 billion in 2015 to just under $3 billion by 2021, representing a compound annual growth rate (CAGR) of 5.3%.
Innovation fund attracting foreign investment, says fund manager
10 March, 2016The Prime Minister's $500 million innovation fund has already attracted significant international interest and will attract offshore investment to the country, according to life sciences fund manager Jeremy Curnock Cook.
